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Abstract
Background: Microembolism is a frequent pathological event during extracorporeal renal replacement therapy (RRT).
Some previous data indicate that microemboli are generated in patients who are undergoing RRT and that these may
contribute to increased cerebrovascular and neurocognitive morbidity in patients with end-stage renal disease. The
current trial aims to quantify the microembolic load and respective qualitative composition that effectively reaches the
intracerebral circulation in critically ill patients treated with different RRT modalities for acute kidney injury (AKI).
Methods/design: The COMET-AKI trial is a prospective, randomized controlled clinical trial with a 2-day clinical
assessment period and follow-up visits at 6 and 12 months. Consecutive critically ill patients with AKI on continuous
renal replacement therapy (CRRT) scheduled for a switch to intermittent renal replacement therapy (IRRT) will be
randomized to either switch to IRRT within the next 24 h or continued CRRT for an additional 24 h. Cerebral
microembolic load will be determined at baseline, i.e., before switch (on CRRT for both groups) and on IRRT
versus CRRT, whichever group they were randomized to. The primary endpoint is defined as the difference in
mean total cerebral microemboli count during the measurement period on CRRT versus IRRT following randomization.
Microemboli will be assessed within the RRT circuit by a 1.5-MHz ultrasound detector attached to the venous RRT
tubing and cerebral microemboli will be measured in the middle cerebral artery using a 1.6-MHz robotic transcranial
Doppler system with automatic classification of Doppler signals as solid or gaseous. In addition to Doppler measurements,
patients will be examined by magnetic resonance imaging and neurocognitive tests to gain better understanding into the
potential morphological and clinical consequences of embolization.
Discussion: The results of COMET-AKI may help to gain a better insight into RRT modality-associated differences regarding
microbubble generation and the cerebral microembolic burden endured by RRT recipients. Furthermore, identification of
covariates of microbubble formation and distribution may help to encourage the evolution of next-generation RRT circuits
including machinery and/or filters.
Trial registration: ClinicalTrials.gov, ID: NCT02621749. Registered on 3 December 2015.
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Background
Patients undergoing renal replacement therapy (RRT) are
frequently disabled, and their quality of life may be limited
by dementia and silent or apparent stroke [1, 2]. Neuroim-
aging studies have revealed an increased prevalence of cere-
bral atrophy and ischemic brain lesions in RRT recipients
compared to the general population following rather short
periods of RRT [3–5]. In addition to traditional cerebrovas-
cular risk factors that predispose patients undergoing RRT
to increased neurological morbidity, microembolic brain in-
jury was postulated a relevant risk factor and generation of
gaseous microemboli (= microbubbles) were observed in
hemodialysis circuits [6, 7]. Microemboli were also detected
in arterio-venous fistulae, the subclavian vein and the ca-
rotid artery of RRT recipients. Notably, this may occur in
the absence of intracardiac right-to-left shunt. Further, it is
assumed that a substantial number of microemboli can
evade bubble alarms in the RRT circuit, may pass the “lung
barrier,” and reach the systemic arterial and cerebral
circulation [8–11].
Several hypotheses exist with respect to the nature and
mechanism of microemboli generation under RRT.
During periods of insufficient anticoagulation on RRT
circuits, the release of solid particles consisting of fibrin
deposits and blood clots was postulated. More recent
reports indicate that microemboli are mostly gaseous in
nature and may arise either from the RRT itself (e.g., due
to poor pre-dialysis de-airing, incorrect operation,
malfunction of the degassing system, leakage, etc.) or
appear as a result of pressure change-induced cavitation
or by temperature gradients within the circuit [3, 6]. To
date, the exact origin of microemboli generation and its
clinical relevance are considered unclear [6].
Microbubbles from the RRT circuit travel within the
bloodstream until they are trapped in the (e.g., pulmonary)
microcirculation where they are slowly dissolved [6]. How-
ever, direct effects of gas bubbles in the microcirculation in-
clude ischemia and pressure changes in blood vessels and
surrounding tissues [11–14]. Pressure on the endothelial
cells results in increased large-pore radius and intercellular
gap formation, increased hydrostatic pressure and
enhanced permeability leading to interstitial edema. These
effects appear potentiated by inflammatory responses and
complement activation, triggering of activated polymorpho-
nuclear leukocytes, and mast cell-derived histamine release,
which results in furthermore increased vascular permeabil-
ity. Activation of endothelial cells and platelets further
results in activation of coagulation cascades and clot forma-
tion in direct proximity to the bubble. This may ultimately
cause a (permanent) elevation of pulmonary artery
pressures via increased pulmonary vascular resistance for
example.
In the intensive care unit (ICU), RRT is typically
provided by a continuous (CRRT) or an intermittent
(IRRT) modality. Both modalities are considered equiva-
lent in terms of clinical outcome and mortality [15–18].
A key difference between respective modalities is appli-
cation of higher blood flow rates in IRRT (i.e., typical
blood flow rates of 200–300 ml/min) compared to CRRT
(i.e., typical blood flow rates: 100–150 ml/min). Thus,
IRRT aims at higher urea solute clearance within a
shorter treatment period (typically 4 h of IRRT applied).
The aim of the COMET-AKI trial is to investigate the
impact of CRRT and IRRT on microbubble/cerebral
microemboli generation in a cohort of critically ill patients
with dialysis-dependent acute kidney injury (AKI). Our
hypothesis is that microbubble generation hemodialysis
circuits and the subsequent number of cerebral microem-
boli is related to the blood flow rate and associated arterial
and venous pressures. As IRRT is associated with higher
blood flow rates and increased dynamic pressure gradi-
ents, IRRT may theoretically generate higher microbubble
rates and thus a larger cerebral microembolic burden.
Methods/design
The cerebral microembolism in the critically ill with
acute kidney injury (COMET-AKI) trial is a prospective,
randomized controlled clinical trial with a 2-day assess-
ment period and follow-up visits at 6 and 12 months.
The primary objective is to investigate the impact of
CRRT and IRRT on microbubble-/-cerebral microemboli
generation in a cohort of critically ill patients with
dialysis-dependent acute kidney injury.
The Cantonal Ethics Committee (CEC) has
approved the study protocol (KEK No. 199/15, ver-
sion 3.0, December 2015). The trial is registered at
ClinicalTrials.gov (NCT02621749). The study will be
performed in accordance with the study protocol and
with principles enunciated in the current version of
the Declaration of Helsinki, the guidelines of Good
Clinical Practice (GCP) issued by the International
Council on Harmonization (ICH), the European
Directive on medical devices 93/42/EEC and the ISO
Norm 14,155 and ISO 14971, and applicable Swiss
Law. COMET-AKI is monitored by the Department
of Anesthesiology and Pain Therapy of the University
of Bern. The study protocol follows the Consolidated
Standards of Reporting Trials (CONSORT) guidelines.
All relevant data will be stored on an in-house
research platform, which is a dedicated server for
research data management.
Study population and patient allocation
Consecutive critically ill patients treated with CRRT for
AKI, and scheduled to be switched (as determined by the
treating ICU physician in charge) to IRRT, will be ran-
domized by an independent computer-based procedure to
either switch to IRRT the next day or to continued CRRT
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for one additional day. Doppler measurements will be
performed during CRRT for both groups before the switch
(baseline, examination day 1) and after the switch (follow-
up measurement, examination day 2) in the CRRT and
IRRT groups, respectively. In the IRRT group, there will be
a RRT pause of 12 h between CRRT termination and
IRRT start in order to allow equilibration and wash out of
potential CRRT-induced microemboli. Transcranial
Doppler (TCD) detection of cerebral microemboli will be
performed bilaterally and continuously in both middle
cerebral arteries (MCAs) for 30 min. Additionally, micro-
bubble generation will be simultaneously recorded in the
RRT circuit by extracorporeal Doppler detector in the
venous tubing, placed 10 cm downstream of the air
detector (Fig. 1). No interventions (e.g., bolus intraven-
ously administered (IV) drug injections, line flushing,
change of infusion rate, blood sampling or other manipu-
lations) will be allowed during Doppler examinations. At
the beginning and at the end of the study period, patients
will undergo routine clinical examinations to evaluate for
neurological and neurocognitive disturbances. A magnetic
resonance imaging (MRI) examination will be performed
after inclusion of the patient in the study and again after
completion of the follow-up Doppler measurements (Fig. 2).
Consent procedure
The investigators will explain to each participant the na-
ture of the study, its purpose, the procedures involved,
the expected duration, the potential risks/benefits or any
potential discomfort. Each participant will be informed
that the participation in the study is voluntary and that
they may withdraw from the study at any time and that
withdrawal of consent will not affect their subsequent
medical assistance and/or treatment. All participants for
the study will be provided with a Participant Information
Sheet and a Consent Form describing the study and pro-
viding sufficient information for the participant to make
an informed decision about their participation in the
Fig. 1 Patient flow diagram with allocation to CRRT versus IRRT. CRRT continuous renal replacement therapy, IRRT intermittent renal replacement
therapy, RRT renal replacement therapy, TTE transthoracic echocardiography examination, TEE transesophageal echocardiography examination,
TCD transcranial Doppler ultrasound, MRI magnetic resonance imaging, CAM-ICU Confusion Assessment Method for the Intensive Care Unit, RASS
Richmond Agitation and Sedation Scale, MoCA Montreal Cognitive Assessment, MCA middle cerebral artery, SF-36 Short Form (36) Health Survey
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study. The formal consent of a participant/next of kin,
using the approved Consent Form, will be obtained be-
fore the participant is submitted to any study-specific
procedure. The participant/next of kin must read and
sign the informed consent and will be given a copy of
the signed document. In case of inability to give consent,
the patient’s legal representative will be asked for the
patient’s participation in the study. In case of deferred
consent and as soon as the patient is able to give
consent, the patient will be informed in detail about
the study. Patients may withdraw from the study at
any stage by oral or written declaration. In case of
withdrawal of informed consent (or in case of non-
compliance, disease progression, safety concerns) all
study relevant data will be anonymized following data
base closure.
Study periods and visits
The study includes a 2-day assessment period/clinical phase
and follow-up visits at 6 and 12 months. During the clinical
phase, participants will attend five study visits. The overall
duration of the clinical phase will be approximately 207
min for each participant.
Procedures at each visit include (Table 1):
Visit 1: Recruitment and screening
Patients/next of kin are recruited on site. If the
treating intensivist identifies a patient whose clinical
status allows switching from CRRT to IRRT, has no
exclusion criteria (especially, no pathology on TTE/
TEE examination) and fulfills the inclusion criteria,
they will inform the patient about the study together
with a study representative and will hand out the
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure: schedule of enrollment, interventions and
assessments for the COMET-AKI trial. CRRT continuous renal replacement therapy, IRRT intermittent renal replacement therapy, TTE
transthoracic echocardiography examination, TEE transesophageal echocardiography examination, TCD transcranial Doppler ultrasound,
MRI magnetic resonance imaging, CAM-ICU Confusion Assessment Method for the Intensive Care Unit, RASS Richmond Agitation and
Sedation Scale, MoCA Montreal Cognitive Assessment, MCA middle cerebral artery, SF-36 Short Form (36) Health Survey
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Patient Information Sheet and Consent Form (in
case of inability to consent: the legal representative/
next of kin will be informed). The treating intensivist
then passes on this information to the principal
investigator (PI) or his designee. If the patient (or
the legal representative) is interested in participating,
the PI will then contact the patient during his visit
on the ICU (in case of inability to consent: the legal
representative will be reached) to inform in detail
about the study and to obtain written informed
consent.
Visit 2: Baseline neurocognitive examinations
The PI (or his designee) performs the clinical
examination and the neurocognitive tests.
Visit 3: Doppler measurements on CRRT
The PI (or his designee) performs the Doppler
measurements during CRRT therapy.
Visit 4: Randomization
At the end of examination day 1, the PI (or his designee)
send out a request for patient randomization to
the external institution performing the computer-
based randomization (CRRT versus IRRT groups).
Visit 5: Doppler measurements on CRRT
The PI (or his designee) performs the Doppler
measurements during CRRT or IRRT.
Visit 6: Follow-up neurocognitive examinations
The PI (or his designee) performs the clinical
examination and the neurocognitive tests. After
6 and 12 months, the SF-36 Health Survey is performed
by the PI (or his designee) by telephone.
Eligibility criteria
Participants fulfilling all of the following inclusion cri-
teria are eligible for the study:
Age aged over 18 years
Written informed consent as documented by the
signature of the patient or their legal representative (in
case of inability to give consent).
The following exclusion criteria apply:
 Presence of atrial septal defect (intracardiac shunting),
severe aortic/mitral valve pathology or valvular
endocarditis in routine transthoracic (TTE) or
transesophageal echocardiography (TEE) examination
(before baseline Doppler measurement)
 Presence of chronic atrial fibrillation or other
irregular cardiac rhythm
 Known cerebrovascular pathology (carotid and/or
vertebral artery stenosis > 70%, cerebrovascular
insult)
 Contraindications for MRI (e.g., pacemaker,
hemodynamic instability precluding patient
transfer to MRI)
Table 1 Study measures at each visit
Visit 1: screening Visit 2: baseline
neurocognitive
examinations
Visit 3: Doppler
measurement CRRT
Visit 4: randomization Visit 5: Doppler
measurement
IRRT or CRRT
Visit 6: follow-up
neurocognitive
examinations
Duration of visit 30 min 60–120 min 90 min 30 min 60–120 min
Recruitment X
Consent Form X
Inclusion/exclusion X
Medical history X
TTE/TEE X
Assess vital signs X X X X X
External randomization X
Clinical examination X X
Doppler examination X X
MRI X X
CAM-ICU X X
RASS X X
MoCA X X
SF-36a X
aAfter 6 and 12 months. CAM-ICU Confusion Assessment Method for the Intensive Care Unit, CRRT continuous renal replacement therapy, IRRT intermittent renal
replacement therapy, MoCA Montreal Cognitive Assessment, SF-36 Short Form (36) Health Survey, MRI, magnetic resonance imaging, RASS Richmond Agitation
and Sedation Scale, TEE transesophageal echocardiography, TTE transthoracic echocardiography
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 Missing bilateral temporal window for transcranial
Doppler ultrasound (TCD) examination
 Allergy to any plastic contained in the investigative
devices (i.e., head frame, TCD probe) or to
ultrasound gel
 Patients with chronic kidney disease (serum
creatinine > 3 mg/dl) and/or patients undergoing
chronic hemodialysis therapy
 Pregnant or lactating patients
 Patients institutionalized for neurological,
psychiatric, and/or neurocognitive reasons
 Inability to follow the procedures of the study, e.g.,
due to language problems, psychological disorders,
dementia, etc. of the participant
 Participation in another study with an
investigational drug within the 30 days preceding
and during the present study
 Recent hospitalization on ICU with RRT
requirement
 Previous enrollment into the current study
Sample size calculation
Based on our preliminary study, [19] we expect a true
difference in the mean high-intensity transient signals
(HITS) value of 700 and a standard deviation of 950
HITS between the two groups of interest. With a desired
power of 0.8 and an alpha of 0.05, the number of re-
quired patients is 58 (29/group). Taking into consider-
ation a dropout rate of 15%, we plan to include a total
number of patients of 66.
Study endpoints and statistical analyses
The primary endpoint is defined as the difference in
mean total cerebral microemboli count during the meas-
urement period on CRRT versus IRRT following
randomization.
Secondary endpoints include:
1. Increase in cerebral microemboli count and rate
(= count/RRT minute) in the middle cerebral artery
in CRRT (CRRT group) versus IRRT (IRRT group)
in relation to the baseline measurement in both
groups during CRRT
2. Increase in microbubble count and rate
(= count/RRT minute) in the venous outflow of
the RRT circuit in CRRT (CRRT group) versus
IRRT (IRRT group) in relation to the baseline
measurement in both groups during CRRT
3. Relationship between the counts/rates of
microbubbles and cerebral microemboli
4. Volume and number of new ischemic lesions on
periprocedural MRI and their correlation to cerebral
microembolic load/microbubble count
5. ICU mortality, in-hospital and 30-day mortality,
intensive care unit length of stay, total hospital
length of stay, days on RRT
6. Relation of the findings to underlying reason for
AKI/need for RRT (descriptive analysis)
7. Relation of the findings with regard to hemodynamic
data, if available (heart rate, systolic blood pressure,
diastolic blood pressure, central venous pressure,
vasopressor usage)
The primary endpoint results from the difference in
mean total cerebral microemboli count in CRRT versus
IRRT recipients compared with analysis of covariance
(ANCOVA). To assess relationships between cerebral
microemboli/microbubble count and the number of is-
chemic lesions on MRI, the Pearson correlation coeffi-
cient will be used. Other parameters will be analyzed in
a descriptive fashion with parametric or non-parametric
statistical methods. A significance level of 0.05 will be
considered.
Study devices and neurocognitive examinations
1. Renal replacement therapy
Continuous renal replacement therapy is provided
by PrismaflexTM (Gambro Hospal GmbH, Danziger
Str. 23, 81,194 Gröbenzell, Germany). Intermittent
renal replacement therapy is provided by Dialog +
(B Braun Melsungen, AG, Carl-Braun-Strasse 1,
34,212 Melsungen, Germany). CRRT will be
performed as follows: continuous veno-venous
hemodialysis and filtration (CVVHDF) applied
daily for 24 h (target) using a poly-sulfone synthetic
membrane and bicarbonate-buffered substitution
fluids (blood flow 150 ml/min, dialysate flow 1000
ml/h, substitute 500 ml/h, if applicable: pre-pump
substitute containing citrate 1500 ml/h). Regional
citrate anticoagulation (at a citrate dose of 3 mmol/l)
will be used as standard anticoagulant. A delivered
CRRT “dose” of > 30 ml/kg body weight/h applies.
IRRT will be performed for 4 h using volumetric
ultrafiltration control, water purified by reverse
osmosis and bicarbonate-buffered dialysate. Blood
flow and dialysate flow will be kept at 300 ml/min
and 500 ml/min, respectively
2. Doppler measurements
Cerebral microemboli detection will be performed
with TCD (Delica 9UA series, Delica, Shenzen,
China), which is equipped with a 1.6-MHz robotic
transducer and a commercially available computer.
The TCD probes will be mounted bilaterally over
the temporal bone window using a dedicated size-
adjustable probe-holder. HITS will be detected using
the current version of EDS software (SMT medical,
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Wurzburg, Germany). TCD measurements
will be performed according to the guidelines
established by the International Consensus
Group on Microembolus Detection. The MCA
will be automatically insonated by the robotic
TCD probes, and the Doppler velocity spectral
range will be adapted to the expected maximum
MCA flow velocity. Power output and gain
settings will be adjusted to provide an optimal
signal-to-noise ratio. On the basis of neural
network technology, the EDS software automatically
classifies every intensity increase within the Doppler
spectrum as a cerebral microembolus (solid or
gaseous) or as an artefact. After microemboli
detection is complete, two experts, blinded to the
study groups, will review all recordings off-line in
order to confirm correct signal detection and
differentiation. Microbubble detection in the RRT
circuit is performed using the CMD-20 1.5-MHz
ultrasound detector (Hatteland Instrumentering,
Røyken, Norway) connected to the venous tubing
and placed 10 cm downstream to the air detector.
The device is a microbubble detector specifically
designed for extracorporeal lines with an operation
principle based on the pulsed Doppler technique;
when the ultrasonic pulse hits a microbubble in the
extracorporeal line the pulse will be partially reflected
to the probe but with a different frequency than the
transmitted wave (Doppler shift). The amplitude of the
Doppler shift is proportional to microbubble diameter
which allows for the possibility to classify both the size
and the count of each microbubble passing the tube
3. Magnetic resonance imaging
Imaging studies are performed on either a 1.5-T or a 3-
T Siemens MRI system (Magnetom Avanto, Magnetom
Trio; Siemens Medical Solution, Erlangen, Germany)
with a 12-channel coil.
The MRI protocol encompasses a routine MRI
protocol with following sequences: axial diffusion-
weighted imaging (DWI), axial fluid-attenuated
inversion recovery (FLAIR), susceptibility-weighted
imaging (SWI), time-of-flight (ToF) angiography
and axial T1wSE post contrast
4. Neurocognitive examination
To access neurocognitive and health disturbances,
patients are subjected to a battery of tests: (1) Confusion
Assessment Method for the Intensive Care Unit (CAM-
ICU), (2) Richmond Agitation and Sedation Scale
(RASS), (3) Montreal Cognitive Assessment (MoCA)
and (4) the Short Form (36) Health Survey (SF-36)
Severe adverse events and safety
Severe adverse events are assessed by the PI and are
Medical Dictionary for Regulatory Activities (MedDRA)-
coded in the Case Report Form (CRF) during the clinical
phase and the follow-up period. All adverse events will
be reported to the CEC in accordance with all national
and institutional requirements.
Quality assurance and control
Study data are recorded manually on the paper CRF
(p-CRF) and entered after completion of the measure-
ments in each participant into an electronic data base
(double data entry). For each enrolled study partici-
pant, a CRF is maintained. CRFs are kept current to
reflect subject status at each phase during the course
of study. Participants cannot be identified in the CRF
by name, initials and/or birth date. Appropriate coded
identification with participant number in combination
with date of the investigation (year, month, day) is
used. Authorization for CRF entries is provided on
the form “Staff education, roles, responsibilities and
signatures” submitted as a unique document to the
CEC.
Specification of source documents
Source data include original documents relating to the
study, as well as the medical treatment and medical
history of the participant. All documents containing
measurements (e.g., CRF) or other patient-related data
(e.g. demographic data, visit dates, participation in study
and Informed Consent Forms, randomization number,
serious adverse events, and concomitant medication,
results of relevant examinations) are considered source
documents.
Record keeping/archiving
All study data will be archived for a minimum of 10
years after study termination or premature termination
of the clinical trial.
Data management
At the departmental research platform, three locally
separated dedicated servers are installed for research
data management. The servers are running on Windows
Server and using SQL Server (Microsoft Corporation,
One Microsoft Way, Redmond, WA 98052-7329, USA)
for the relational data base. The web application LabKey
Server is implemented in Java and is running on the
Apache Tomcat web server. The data are stored in
relational data base engines such as PostgreSQL or
Microsoft SQL server.
Data security, access and backup
LabKey Server provides web application security and
can be configured for Secure Socket Layer (SSL)-
encrypted data transfer. The application has a group and
role-based security model. Each user belongs to one or
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more security groups with specific sets of permissions in
relation to folder or projects in the system. Only dedi-
cated site administrators have access to the administra-
tion console enabling user management and changing
security settings. Data are stored and visualized in data
grids either in the format of datasets, lists or assays.
Each change of data is tracked and documented in
corresponding audit log files. The system can only be
accessed entering a user name and password. All events
are recorded in the user event list of the audit log files.
The application is running on a productive server with
an image on a backup server. In addition, a regularly
backup of the whole data base is implemented using
storage servers.
Analysis and archiving
LabKey Server provides data analysis by integrated tools
for creating filtered views and charts. All data can be
exported in different formats (Excel, text, queries)
suitable for transfer to a statistical software package of
choice. In addition, data can be analyzed creating R
views. All data will be archived and secured in the data
base as long as required by legislation.
Electronic and central data validation
Data validity will be controlled by cross-checking the
p-CRFs and the electronic data bases.
Dissemination policy
We plan to publish the data in a peer-reviewed, high-
ranking clinical journal.
Discussion
The cerebral microembolic burden during RRT may rep-
resent an underestimated problem that can contribute to
neurological complications and adverse clinical out-
comes. Associated repeated hospital stays and outpatient
follow-ups can be considered potential additional factors
leading to an increase in healthcare costs. We expect
that COMET-AKI provides more detailed insight in RRT
modality-associated differences with regard to micro-
bubble generation and cerebral microembolic burden.
Currently, it seems generally accepted by physicians
and manufacturers that microbubbles are generated
within the RRT circuit and that some bubbles may enter
the patient’s cerebral circulation during RRT sessions.
With no apparent immediate clinical side effects for
RRT-treated patients, the problem of microbubbles in
RRT patients appears currently not within the scope of
interest. If a significant number of microbubbles would
indeed be detected within the systemic circulation of the
patient (i.e., in the cerebral vessels), the potential prob-
lem of microbubbles in RRT recipients may become
even more significant. Our data may further provide the
scientific basis for longitudinal studies relating cerebral
microbubbles to changes in cognitive functions. Further-
more, identification of covariates of bubble formation
and distribution may help to encourage the evolution of
next-generation RRT circuits, machinery, and/or filters
with reduced microbubble generation and distribution
(Additional file 1).
Trial status
Recruitment started in October 2016 and is estimated to
be completed in October 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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